Clinical Trial Update: Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 trial of guadecitabine in higher-risk myelodysplastic syndromes has been completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Guadecitabine (guadecitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: High Risk Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-07-17